Drug Profile
AZD 0865
Alternative Names: AR-H044277; AZD 865; AZD0865; Front-loadedLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antiulcers
- Mechanism of Action Potassium-competitive acid blockers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gastro-oesophageal reflux
Most Recent Events
- 28 Jul 2005 Discontinued - Phase-II for Gastro-oesophageal reflux in Europe (PO)
- 31 May 2005 Data presented at the Digestive Disease Week-2005 (DDW-2005) have been added to the adverse events, pharmacokinetics and Peptic Ulcer Disease pharmacodynamics sections ,
- 12 Jan 2005 A preclinical study has been added to the Peptic Ulcer Disease pharmacodynamics section